Friday, September 22, 2023
SCIENMAG: Latest Science and Health News
No Result
View All Result
  • Login
  • HOME PAGE
  • BIOLOGY
  • CHEMISTRY AND PHYSICS
  • MEDICINE
    • Cancer
    • Infectious Emerging Diseases
  • SPACE
  • TECHNOLOGY
  • CONTACT US
  • HOME PAGE
  • BIOLOGY
  • CHEMISTRY AND PHYSICS
  • MEDICINE
    • Cancer
    • Infectious Emerging Diseases
  • SPACE
  • TECHNOLOGY
  • CONTACT US
No Result
View All Result
Scienmag - Latest science news from science magazine
No Result
View All Result
Home SCIENCE NEWS Medicine & Health

Some FDA-approved drugs could be repurposed to treat people infected with COVID-19

September 9, 2021
in Medicine & Health
0
Share on FacebookShare on Twitter

Despite the development of SARS-CoV-2 vaccines, effective therapeutics are needed until worldwide immunity has been achieved. A study published in PLOS Pathogens by Adam Pickard and Karl Kadler at University of Manchester, United Kingdom, and colleagues suggests that some FDA-approved drugs could be safely repurposed to treat COVID-19 infections.

Some FDA-approved Drugs Could Be Repurposed to Treat People Infected with COVID-19

Credit: Yinhui Lu, Pickard A et al., 2021, PLOS Pathogens, CC-BY 4.0 (https://creativecommons.org/licenses/by/4.0/)

Despite the development of SARS-CoV-2 vaccines, effective therapeutics are needed until worldwide immunity has been achieved. A study published in PLOS Pathogens by Adam Pickard and Karl Kadler at University of Manchester, United Kingdom, and colleagues suggests that some FDA-approved drugs could be safely repurposed to treat COVID-19 infections.

The majority of the world’s population is still unvaccinated, yet there are few medications that have been proven safe, easily distributed, and capable of reducing the spread of SARS-CoV-2. To identify drugs that could effectively treat SARS-CoV-2 infections, researchers performed a screen of 1971 FDA-approved therapeutics using a luminescent enzyme tagged version of SARS-CoV-2 virus in order to quantify viral load. They then analyzed the efficacy of the drugs in a range of infected human cell types, observing how well the virus replicated in infected cells after exposure to each medication.

The authors identified nine drugs effective in suppressing virus replication in SARS-CoV-2 infected cells already infected with SARS-CoV-2. However, the study was limited in that it was only conducted in human cells and the drugs have yet to be tested for efficacy in treating SARS-CoV-2 in patients. Clinical trials are needed to determine whether the drugs are suitable therapeutics for COVID-19 patients.

According to the authors, “Our study has identified compounds that are safe in humans and show effectiveness in reducing SARS-CoV-2 infection and replication in human cells.  As these drugs are FDA-approved and with safe dosimetry already established for use in patients, clinical trials could be initiated for these drugs within a relatively short time frame.”

Kadler adds, “We identify drugs that stop replication of the SARS-CoV-2 virus (which is the cause of COVID-19) in human cells in culture. The drugs include ebastine, which is approved by the FDA for the treatment of Pneumocystis jirovecii (Pneumocystis carinii) pneumonia, and vitamin D3, which is available over the counter, and could prove powerful additions to the treatment of COVID-19.  These drugs have not been evaluated in patients with COVID-19 and are not alternatives to existing treatments or vaccination programs.”

###

 

In your coverage, please use this URL to provide access to the freely available article in PLOS Pathogens: http://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1009840

Citation: Pickard A, Calverley BC, Chang J, Garva R, Gago S, Lu Y, et al. (2021) Discovery of re-purposed drugs that slow SARS-CoV-2 replication in human cells. PLoS Pathog 17(9): e1009840. https://doi.org/10.1371/journal.ppat.1009840

Funding: The research was funded by Wellcome (London) (110126/Z/15/Z and 203128/Z/16/Z) to KEK. SG was funded by the NIHR Manchester Research Centre and the Fungal Infection Trust. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.



Journal

PLoS Pathogens

DOI

10.1371/journal.ppat.1009840

Method of Research

Experimental study

Subject of Research

People

COI Statement

The authors have declared that no competing interests exist.

Tags: COVID19DrugsFDAapprovedinfectedpeoplerepurposedtreat
Share26Tweet17Share5ShareSendShare
  • blank

    Null results research now published by major behavioral medicine journal

    1031 shares
    Share 412 Tweet 258
  • CityU researchers develop novel photo-oxidation therapy for anticancer treatment

    66 shares
    Share 26 Tweet 17
  • Ethylene boosts plant yield and vigor

    67 shares
    Share 27 Tweet 17
  • Researchers issue urgent call to save the world’s largest flower -Rafflesia – from extinction

    67 shares
    Share 27 Tweet 17
  • New study finds that sewage release is worse for rivers than agriculture

    64 shares
    Share 26 Tweet 16
  • Bridging the gap: new terrain smoothing method refines downslope windstorm modeling in the grey zone

    64 shares
    Share 26 Tweet 16
ADVERTISEMENT

About us

We bring you the latest science news from best research centers and universities around the world. Check our website.

Latest NEWS

Null results research now published by major behavioral medicine journal

Corning® launches Videodrop, revolutionizing real-time nanoparticle detection and analysis

Grant awarded to University of Louisville law professor will fund climate adaptation project

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 208 other subscribers

© 2023 Scienmag- Science Magazine: Latest Science News.

No Result
View All Result
  • HOME PAGE
  • BIOLOGY
  • CHEMISTRY AND PHYSICS
  • MEDICINE
    • Cancer
    • Infectious Emerging Diseases
  • SPACE
  • TECHNOLOGY
  • CONTACT US

© 2023 Scienmag- Science Magazine: Latest Science News.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In